Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulotaront PET study in schizophrenia
NCT04038957Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Aug 2019
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ulotaront in schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Change From Baseline in Dopamine Synthesis Capacity Using 18F-DOPA at 2 weeks. Started Aug 2019; status: completed.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04038957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04038957.